Previous 10 | Next 10 |
Mesoblaston (MESO) +68% after announcing additional results from the DREAM-HF Phase 3 trial.TransEnterix (TRXC) +64%.LM Funding America (LMFA) +49%.Aileron Therapeutics (ALRN) +35%.Bionano Genomics (BNGO) +24% after announcing first publication from the COVID-19 host genome structur...
EyeGate Pharmaceuticals ([[EYEG]] +5.9%) has entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of ~$8M.EyeGate will issue to Armistice an aggregate of 1,531,101 shares of the its common ...
WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the e...
Gainers: Anterix (ATEX) +67%.NantKwest (NK) +55%.500.com Limited (WBAI) +51%.Editas Medicine (EDIT) +47%.EyeGate Pharmaceuticals (EYEG) +45%.Organovo Holdings (ONVO) +36%.Nuverra Environmental Solutions (NES) +33%.RealPage (RP) +29%.Agios Pharmaceuticals (AGIO) +29%.CuriosityStream (CURI...
Gainers: EyeGate Pharmaceuticals (EYEG) +78%, Editas Medicine (EDIT) +42%, NantKwest (NK) +30%, Liminal BioSciences (LMNL) +29%, Agios Pharmaceuticals (AGIO) +24%.Losers: Scopus BioPharma (SCPS) -17%, uniQure (QURE) -16%, C...
EyeGate Pharmaceuticals (EYEG) +87% as it acquires Panoptes Pharma.NantKwest (NK) +32% as its partner, ImmunityBio, achieves primary endpoint in bladder cancer study.RealPage (RP) +31% as Thoma Bravo has agreed to buy the company for $9.6B.China Customer Relations Centers (CCRC...
EyeGate Pharmaceuticals (EYEG) is acquiring Belgium-based Panoptes Pharma for $4M in cash and stock to broaden its pipeline targeting eye disorders. The shares of EyeGate have surged +67.8% in pre-market trading.As part of the deal, the co-founders of Panoptes, Dr. Franz Obermayr, a...
Expands Pipeline Beyond Ophthalmology with PP-001 , a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and Picomolar Potency to Avoid Off-Target Side Effects Acquisition Str...
Eyegate Pharmaceuticals (EYEG): Q3 GAAP EPS of -$0.44 misses by $0.02.Cash and cash equivalents of $2.93M10QPress Release For further details see: Eyegate Pharmaceuticals EPS misses by $0.02
WALTHAM, MA / ACCESSWIRE / November 9, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended September 30, 2020 and pr...
News, Short Squeeze, Breakout and More Instantly...
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from F...
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announc...